William Fraser

William Fraser


Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Bone
Verified
Journal Article
Closed access
MPMaria Papageorgiou
Maria Papageorgiou
KEKirsty Elliott-Sale
Kirsty Elliott-Sale
APAlan Parsons
Alan Parsons
JTJohnathan C.Y. Tang
Johnathan C.Y. Tang
JGJulie P. Greeves
Julie P. Greeves
CSCraig Sale
Craig Sale

1 January 2010 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
ALAnne L Langston
Anne L Langston
MCMarion K Campbell
Marion K Campbell
WFWilliam Fraser
William Fraser
GMGraeme S MacLennan
Graeme S MacLennan
PSPeter L Selby
Peter L Selby
SRStuart Ralston
Stuart Ralston
Bisphosphonates are widely regarded as the treatment of choice for Paget's disease of bone (PDB) because of their potent inhibitory effects on bone turnover, but the effects of bisphosphonate therapy on symptoms and complications of PDB have been little studied. Here we report the results of a randomized trial that compared the effects of symptomatic treatment with intensive bisphosphonate therapy in a cohort of 1324 patients with PDB who were followed up for a median of 3 years (range 2 to 5 years). The symptomatic treatment group was treated only if they had pagetic bone pain, for which they were first given analgesics or anti-inflammatory drugs, followed by bisphosphonates if they did not respond. The intensive group received repeat courses of bisphosphonates irrespective of symptoms with the aim of reducing and maintaining serum alkaline phosphatase (ALP) levels within the normal range. The endpoints were fracture, orthopedic surgery, quality of life, bone pain, and hearing thresholds. Serum ALP levels were significantly lower in the intensive treatment group than in with the symptomatic treatment group within 4 months of commencing treatment and remained lower throughout the study (p < .001). There was no difference between the groups in quality of life (as assessed by the SF36 questionnaire), in overall bodily pain, or in pagetic bone pain. Hearing thresholds, as assessed by audiometry did not change significantly and did not differ between the treatment groups. Clinical fractures occurred in 46 of 661 patients (7.0%) in the intensive treatment group compared with 49 of 663 patients (7.4%) in the symptomatic treatment group, and orthopedic surgery was required in 50 of 661 patients (7.3%) in the intensive treatment group and in 55 of 663 patients (8.3%) in the symptomatic treatment group. These differences were not significant. Subgroup analyses of patients with elevated ALP levels at baseline and those who did or did not receive bisphosphonates during the study yielded similar results to those in the study group as a whole. We conclude that striving to maintain normal ALP levels with intensive bisphosphonate therapy confers no clinical advantage over symptom-driven management in patients with established PDB. Neither management strategy had a significant beneficial impact on pain or quality of life (Clinical trial registration number ISRCTN12989577). © 2010 American Society for Bone and Mineral Research

13 January 2013 in Calcified Tissue International
Verified
Journal Article
Closed access
WFWilliam Fraser
William Fraser
AMAnna Milan
Anna Milan

1 September 2018 in Bone
Verified
Journal Article
Closed access
MPMaria Papageorgiou
Maria Papageorgiou
DMDan Martin
Dan Martin
HCHannah Colgan
Hannah Colgan
Simon CooperSimon Cooper
Simon Cooper
JGJulie P. Greeves
Julie P. Greeves
CSCraig Sale
Craig Sale

18 November 2019 in Calcified Tissue International
Verified
Journal Article
Open access
PDF file
WFWilliam Fraser
William Fraser
Jonathan TangJonathan Tang
Jonathan Tang
JDJohn J. Dutton
John J. Dutton
ISInez Schoenmakers
Inez Schoenmakers
The demand for measurement of vitamin D metabolites for clinical diagnosis and to advance our understanding of the role of vitamin D in human health has significantly increased in the last decade. New developments in technologies employed have enabled the separation and quantification of additional metabolites and interferences. Also, developments of immunoassays have changed the landscape. Programmes and materials for assay standardisation, harmonisation and the expansion of the vitamin D external quality assurance scheme (DEQAS) with the provision of target values as measured by a reference measurement procedure have improved standardisation, quality assurance and comparability of measurements. In this article, we describe developments in the measurement of the commonly analysed vitamin D metabolites in clinical and research practice. We describe current analytical approaches, discuss differences between assays, their origin, and how these may be influenced by physiological and experimental conditions. The value of measuring metabolites beyond 25 hydroxyvitamin D (25(OH)D), the marker of vitamin D status, in routine clinical practice is not yet confirmed. Here we provide an overview of the value and application of the measurement of 1,25 dihydroxyvitamin D, 24,25 dihydroxyvitamin D and free 25OHD in the diagnosis of patients with abnormalities in vitamin D metabolism and for research purposes.

1 August 2019 in Bone
Verified
Journal Article
Closed access
TOThomas J. O'LEary
Thomas J. O'LEary
RIRachel M. Izard
Rachel M. Izard
NWNeil P. Walsh
Neil P. Walsh
Jonathan TangJonathan Tang
Jonathan Tang
WFWilliam Fraser
William Fraser
JGJulie P. Greeves
Julie P. Greeves